|
1
|
American Cancer Society: Lung cancer: What
are the key statistics about lung cancer. http://www.cancer.org/cancer/lungcancer-non-small-cell/detailedguide/non-smallcell-lung-cancer-key-statistics
(Accessed 12/3/2012) Last revised: 10/12/2012.
|
|
2
|
American Lung Association: Lung Cancer
Fact Sheet. http://www.lung.org/lung-disease/lung-cancer/resources/facts-figures/lung-cancer-fact-sheet.html
(Accessed 12/3/2012) Last revised 2012.
|
|
3
|
American Cancer Society: Malignant
Mesothelioma. http://www.cancer.org/cancer/malignantmesothelioma/detailedguide/malignant-mesothelioma-survival-statistics
(Accessed 12/3/2012) Last revised 9/20/2012.
|
|
4
|
Fidler IJ: Molecular biology of cancer:
invasion and metastasis. Cancer: Principles and Practice of
Oncology. 5th edition. De Vita VT, Hellman S and Rosenberg SA:
Lippincott-Raven; Philadelphia, PA: pp. 135–152. 1997
|
|
5
|
Egeblad M and Werb Z: New functions for
the matrix metalloproteinases in cancer progression. Nat Rev
Cancer. 2:161–174. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Folkman J: Role of angiogenesis in tumor
growth and metastasis. Semin Oncol. 29(Suppl 16): 15–18. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Chambers AF and Matrisian LM: Changing
views on the role of matrix metalloproteinases in metastasis. J
Natl Cancer Inst. 89:1260–1270. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kleiner DL and Stetler-Stevenson WG:
Matrix metalloproteinases and metastasis. Cancer Chemother
Pharmacol. 43(Suppl): S42–S51. 1999. View Article : Google Scholar
|
|
9
|
Yurchenko PD and Schitny JC: Molecular
architecture of basement membranes. FASEB J. 4:1577–1590.
1990.PubMed/NCBI
|
|
10
|
Barsky SH, Siegel GP, Jannotta F and
Liotta LA: Loss of basement membrane components by invasive tumors
but not by their benign counterparts. Lab Investig. 49:140–147.
1983.PubMed/NCBI
|
|
11
|
Liotta LA, Tryggvason K, Garbisa A, Hart
I, Foltz CM and Shafie S: Metastatic potential correlates with
enzymatic degradation of basement membrane collagen. Nature.
284:67–68. 1980. View
Article : Google Scholar : PubMed/NCBI
|
|
12
|
Nelson AR, Fingleton B, Rothenberg ML and
Matrisian LM: Matrix metalloproteinases: biologic activity and
clinical implications. J Clin Oncol. 18:1135–1149. 2000.PubMed/NCBI
|
|
13
|
Schültz A, Schneidenbach D, Aust G,
Tannpfel A, Steinert M and Wittekind C: Differential expression and
activity status of MMP-1, MMP-2 and MMP-9 in tumor and stromal
cells of squamous cell carcinomas of the lung. Tumor Biol.
23:179–184. 2002.PubMed/NCBI
|
|
14
|
Takashi M, Takashi M, Kazumitsu O, Kazuo
K, Yoshio N, Fujio N, Mamoru K, Motohiko F, Nanao N and Yukiyasu N:
Analysis of circulating plasma matrix metalloproteinases (MMP) and
tissue inhibitors of MMP in lung cancer patients. J Nihon Univ Med
Assoc. 59:97–102. 2000.
|
|
15
|
Hirano H, Tsugu M, Kizaki T, Sashikata T,
Yosgi Y, Okada Y and Mori H: Expression of matrix
metalloproteinases, tissue inhibitors of metalloproteinase,
collagens and ki67 antigen in pleural malignant mesothelioma: an
immunohistochemical and electron microscopic study. Med Electron
Microsc. 35:16–23. 2002. View Article : Google Scholar
|
|
16
|
Edwards JC, McLaren J, Jones JL, Walker DA
and O’Byrne KJ: Matrix metalloproteinases 2 and 9 (gelatinases A
and B) expression in malignant mesothelioma and benign pleura. Br J
Cancer. 88:1553–1559. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Werle B, Kotzsch M, Lah TT, Kos J,
Gabrielcic-Geiger D, Spiess E, Schirren J, Ebert W, Fiehn W, Luther
T, Magdolen V, Schmitt N and Harbeck N: Cathepsin B, plasminogen
activator-inihbitor (PAI-1) and plasminogen activator-receptor
(uPAR) are prognostic factors for patients with non-small cell lung
cancer. Anticancer Res. 24:4147–4161. 2004.
|
|
18
|
Shetty S, Kumar A, Johnson A, Pueblitz S
and Idell S: Urokinase receptor in human malignant mesothelioma
cells: role in tumor cell mitogenesis and proteolysis. Am J Physiol
Lung Cell Mol Physiol. 268:L972–L982. 1995.PubMed/NCBI
|
|
19
|
Stetler-Stevenson WG: The role of matrix
metalloproteinases in tumor invasion, metastasis and angiogenesis.
Surg Oncol Clin North Am. 10:383–392. 2001.PubMed/NCBI
|
|
20
|
Stetler-Stevenson WG: Type IV collagenases
in tumor invasion and metastasis. Cancer Metastasis Rev. 9:289–303.
1990. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Dano K, Andreasen PA, Grondahl-Hansen J,
Kristensen P, Nielsen LS and Skriver L: Plasminogen activators,
tissue degradation and cancer. Adv Cancer Res. 44:139–266. 1985.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Duffy MJ, Duggan C, Mulcahy HE, McDermott
EW and O’Higgins NJ: Urokinase plasminogen activator: a prognostic
marker in breast cancer including patients with axillary
node-negative disease. Clin Chem. 44:1177–1183. 1998.
|
|
23
|
Henneke I, Greschus S, Saval R, Korfel M,
Markart P, Mahavadi P, Schermuly RT, Wygrecka M, Strüzebecher J,
Seeger W, Günther A and Ruppert C: Inhibition of urokinase activity
reduces primary tumor growth and metastasis formation in a murine
lung carcinoma model. Am J Respir Crit Care Med. 181:612–619. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Idell S, Pueblitz S, Emri S, Gungen Y,
Gray L, Kumar A, Holiday D, Koenig KB and Johnson AR: Regulation of
fibrin deposition by malignant mesothelioma. Am J Pathol.
147:1318–1329. 1995.PubMed/NCBI
|
|
25
|
Rath M and Pauling L: Plasmin-induced
proteolysis and the role of apoprotein(a), lysine and synthetic
analogs. Orthomolecular Med. 7:17–23. 1992.
|
|
26
|
Andreasen PA, Kjøller L, Christensen L and
Duffy MJ: The urokinase-type plasminogen activator system in cancer
metastasis: a review. Int J Cancer. 72:1–22. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Niedzwiecki A, Roomi MW, Kalinovsky T and
Rath M: Micronutrient synergy - a new tool in effective control of
metastasis and other key mechanisms of cancer. Cancer Metastasis
Rev. 29:529–543. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Roomi MW, Monterrey JC, Kalinovsky T,
Niedzwiecki A and Rath M: Inhibition of invasion and MMPs by a
nutrient mixture in human cancer cell lines: a correlation study.
Exp Oncol. 32:243–248. 2010.PubMed/NCBI
|
|
29
|
Roomi MW, Ivanov V, Kalinovsky T,
Niedzwiecki A and Rath M: In vivo and in vitro anti-tumor effect of
a unique nutrient mixture on lung cancer cell line A-549. Exp Lung
Res. 32:441–453. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Amin ARMR, Kucek O, Khuri FR and Shin DM:
Perspectives for cancer prevention with natural compounds. J Clin
Oncol. 27:2712–2725. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Roomi MW, Monterrey JC, Kalinovsky T, Rath
M and Niedzwiecki A: Comparative effects of EGCG, green tea and a
nutrient mixture on the patterns of MMP-2 and MMP-9 expression in
cancer cell lines. Oncol Rep. 24:747–757. 2010.PubMed/NCBI
|
|
32
|
Sun Z, Chen YH, Wang P, Zhang J, Gurewich
V, Zhang P and Liu JN: The blockage of high-affinity lysine binding
sites of plasminogen by EACA significantly inhibits
prourokinase-induced plasminogen activation. Biochem Biophys Acta.
1596:182–192. 2002.PubMed/NCBI
|
|
33
|
Kemberling JK, Hampton JA, Keck RW, Gomez
MA and Selman SH: Inhibition of bladder tumor growth by the green
tea derivative epigallocatechin-3-gallate. J Urol. 170:773–776.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Sato D and Matsushima M: Preventive
effects of urinary bladder tumors induced by
N-butyl-N-(4-hydroxybutyl)-nitrosamine in rat by green tea leaves.
Int J Urol. 10:160–166. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Valcic S, Timmermann BN, Alberts DS,
Wachter GA, Krutzsch M, Wymer J and Guillen JM: Inhibitory effect
of six green tea catechins and caffeine on the growth of four
selected human tumor cell lines. Anticancer Drugs. 7:461–468. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Mukhtar H and Ahmed N: Tea polyphenols:
prevention of cancer and optimizing health. Am J Clin Nutr.
71:S1698–S1702. 2000.PubMed/NCBI
|
|
37
|
Yang GY, Liao J, Kim K, Yurtow EJ and Yang
CS: Inhibition of growth and induction of apoptosis in human cancer
cell lines by tea polyphenols. Carcinogenesis. 19:611–616. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Taniguchi S, Fujiki H, Kobayashi H, Go H,
Miyado K, Sadano H and Shimikawa R: Effect of (-) epigallocatechin
gallate, the main constituent of green tea, on lung metastasis with
mouse B16 melanoma cell lines. Cancer Lett. 65:51–54. 1992.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Hara Y: Green tea: Health Benefits and
Applications. Marcel Dekker; New York, NY, Basel: 2001, View Article : Google Scholar
|
|
40
|
Kawakami S, Kageyama Y, Fujii Y, Kihara K
and Oshima H: Inhibitory effects of N-acetyl cysteine on invasion
and MMP 9 production of T24 human bladder cancer cells. Anticancer
Res. 21:213–219. 2001.PubMed/NCBI
|
|
41
|
Morini M, Cai T, Aluigi MG, Noonan DM,
Masiello L, De Floro S, D’Agostinin F, Albini A and Fassima G: The
role of the thiol N-acetyl cysteine in the prevention of tumor
invasion and angiogenesis. Int J Biol Markers. 14:268–271.
1999.PubMed/NCBI
|
|
42
|
Yoon SO, Kim MM and Chung AS: Inhibitory
effects of selenite on invasion of HT 1080 tumor cells. J Biol
Chem. 276:20085–20092. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Naidu KA, Karl RC and Coppola D:
Antiproliferative and proapoptotic effect of ascorbyl stearate in
human pancreatic cancer cells: association with decreased
expression of insulin-like growth factor 1 receptor. Dig Dis Sci.
48:230–237. 2003. View Article : Google Scholar
|
|
44
|
Anthony HM and Schorah CJ: Severe
hypovitaminosis C in lung-cancer patients: the utilization of
vitamin C in surgical repair and lymphocyte-related host
resistance. Br J Cancer. 46:354–367. 1982. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Maramag C, Menon M, Balaji KC, Reddy PG
and Laxmanan S: Effect of vitamin C on prostate cancer cells in
vitro: effect on cell number, viability and DNA synthesis.
Prostate. 32:188–195. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Koh WS, Lee SJ, Lee H, Park C, Park MH,
Kim WS, Yoon SS, Park K, Hong SI, Chung MH and Park CH:
Differential effects and transport kinetics of ascorbate
derivatives in leukemic cell lines. Anticancer Res. 8:2487–2493.
1998.PubMed/NCBI
|
|
47
|
Chen Q, Espey MG, Krishna MC, Mitchell JB,
Corpe CP, Buettner GR, Shacter E and Levine M: Pharmacologic
ascorbic acid concentrations selectively kill cancer cells: Action
as a pro-drug to deliver hydrogen peroxide to tissues. Proc Natl
Acad Sci USA. 102:13604–13609. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Nunez C, Ortiz de Apodaca Y and Ruiz A:
Ascorbic acid in the plasma and blood cells of women with breast
cancer. The effect of consumption of food with an elevated content
of this vitamin. Nutr Hosp. 10:368–372. 1995.PubMed/NCBI
|
|
49
|
Kurbacher CM, Wagner U, Kolster B,
Andreotti PE, Krebs D and Bruckner HW: Ascorbic acid (vitamin C)
improves the antineoplastic activity of doxorubicin, cisplatin and
paclitaxel in human breast carcinoma cells in vitro. Cancer Lett.
103:183–189. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Cooke JP and Dzau VJ: Nitric oxide
synthase: role in the genesis of vascular disease. Annu Rev Med.
48:489–509. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Roomi MW, Ivanov V, Netke SP, Niedzwiecki
A and Rath M: Serum markers of the liver, heart and kidney and
lipid profile and histopathology in ODS rats treated with nutrient
synergy. J Am Coll Nutr. 22:77abs. 86. 2003.
|
